SYNERGY(SZ:300636)2025-04-24 10:30Financial Performance - The company reported a total revenue of 1.2 billion yuan for the fiscal year 2024, representing a year-on-year growth of 15%[15]. - The company's operating revenue for 2024 reached ¥758,890,499.03, representing a 5.09% increase compared to ¥722,138,705.43 in 2023[20]. - The net profit attributable to shareholders for 2024 was ¥106,584,102.17, a slight increase of 0.57% from ¥105,983,257.15 in 2023[20]. - The company achieved a sales revenue of 758.89 million yuan in the reporting period, representing a year-on-year growth of 5.09%[64]. - The external sales revenue reached 614.02 million yuan, an increase of 6.76% compared to the same period last year[64]. - The company reported a significant increase in revenue, achieving a year-over-year growth of 25% in Q1 2024, totaling 1.5 billion RMB[130]. - The company provided a forward guidance of 10% revenue growth for the next quarter, projecting revenues between $900 million and $950 million[126]. - The company reported a gross margin of 45%, indicating strong operational efficiency[130]. Research and Development - The company is investing 50 million yuan in R&D for new pharmaceutical products in 2024[15]. - The average R&D investment over the past three years accounts for 8.34% of sales, indicating a strong commitment to innovation and technology development[34]. - The R&D team consists of over 500 professionals, ensuring a robust pipeline of new products and technologies[55]. - Research and development investment amounted to 59.45 million yuan, accounting for 7.83% of the current operating revenue, maintaining a high investment level[64]. - The company is currently in the verification phase for multiple R&D projects aimed at enhancing product competitiveness and market presence[80]. - The company is investing heavily in R&D, with a budget increase of 30% for new technology development in 2024[130]. - The company has completed 18 technology development and process optimization projects during the reporting period, with 12 APIs and 8 intermediates undergoing pilot and trial production[68]. Market Expansion - The company aims to expand its market presence in Southeast Asia, targeting a 20% increase in sales in that region by 2025[15]. - The company is actively expanding into domestic markets, having submitted multiple projects for approval with several large and medium-sized pharmaceutical companies[34]. - The company plans to maintain a balance between entering high-end markets for higher sales prices and retaining competitiveness in low-end markets[106]. - The company will prioritize international markets for product sales while also investing more resources to expand its domestic market presence[107]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by the end of the fiscal year[126]. - Market expansion plans include entering two new regions, aiming for a 10% market share in each by the end of 2024[130]. Corporate Governance - The company has established a governance structure that includes a shareholders' meeting, board of directors, supervisory board, and management team, ensuring a coordinated and balanced mechanism among these entities[136]. - The company has appointed three independent directors to enhance the objectivity and fairness of board decisions[136]. - The company has a complete set of governance regulations, including articles of association and rules for shareholders' meetings, board meetings, and supervisory meetings[136]. - The company has implemented a "Quality and Return Dual Improvement" action plan, although details on its disclosure were not provided[134]. - The company is committed to improving its internal control systems to enhance governance levels[136]. - The company has established a complete and independent financial institution, with a sufficient number of dedicated financial accounting personnel and an independent accounting system and financial management system[146]. Environmental and Safety Management - The company emphasizes environmental protection and has advanced wastewater and air treatment capabilities, with a wastewater treatment capacity of 1,500 tons per day in one plant[61]. - The company has established a comprehensive safety management system, including a safety production committee led by the general manager, to ensure compliance with safety regulations[120]. - The company is continuously investing in environmental protection facilities and optimizing production processes to meet increasingly stringent environmental standards[120]. Employee Management and Compensation - The company emphasizes enhancing employee performance through a competitive compensation policy, including salaries, benefits, and performance-based bonuses[177]. - The training program aims to improve employee skills and competencies, focusing on regular training, professional skills, and management knowledge[178]. - The total pre-tax remuneration for the company's directors, supervisors, and senior management during the reporting period amounted to 6.8491 million yuan[164]. - The highest remuneration was received by the Chairman and General Manager, Mr. Pang Zhengwei, totaling 928,100 yuan[164]. - The company has a total of 1,418 employees, with a professional composition including 717 production personnel, 30 sales personnel, 541 technical personnel, 9 financial personnel, and 121 administrative personnel[175]. Strategic Initiatives - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[15]. - The company plans to invest $100 million in marketing to support new product launches and market expansion efforts[126]. - The company aims to conduct timely mergers and acquisitions to extend its industry chain and enhance its scale and strength[116]. - The company has completed CDE approvals for several products, including Venlafaxine Hydrochloride and Celecoxib, positioning itself as a major supplier in the domestic market[41]. Risks and Challenges - The company has identified key risks including regulatory changes and market competition, which may impact future performance[5]. - The company faces risks related to the loss of core technical personnel, which could impact its competitive advantage and operational stability[123]. - The company's export revenue constitutes a significant portion of its total revenue, making it vulnerable to exchange rate fluctuations, particularly with the appreciation of the RMB against the USD[124].